HOME
>
臨床医学：内科
>
腎臓
> Year Book of RCC 2018

Year Book of RCC 2018

出版社：	メディカルレビュー社
著者：	冨田善彦金山博臣植村天受篠原信雄(編)
発行日：	2019-01-07
分野：	臨床医学：内科 > 腎臓
ISBN：	9784779221842
電子書籍版：	2018-12-31 （第1版第1刷）

書籍・雑誌

≪全国送料無料でお届け≫

品切れ

5,280 円(税込)

電子書籍

章別単位での購入はできません

ブラウザ、アプリ閲覧

5,280 円(税込)

購入する

商品紹介

免疫チェックポイント阻害薬の副作用マネジメントの実際について、各領域のエキスパートが解説。ニボルマブ治療後の治療法の選択や治療の切り替えのタイミングについてのディスカッションなども収録する。

目次

I　Round Table Discussion
　　Post I-O drug　―免疫チェックポイント阻害薬後の治療―

II　Topics of RCC～免疫チェックポイント阻害薬の副作用マネジメントの実際
　　　　　　　　　　（IO-IO combinationを視野に入れて）～
　１．症例の経験から（副作用の概観）
　　１）潰瘍性大腸炎に類似した大腸炎（grade3）と硬化性胆管炎（grade 5）の経験
　　２）当院におけるirAE（尿細管間質性腎炎、腸管気腫症、急性副腎不全）の経験
　２．各副作用のマネジメントの実際
　　１）肺障害
　　２）大腸炎
　　３）肝障害
　　４）心障害
　　５）甲状腺・下垂体・副腎障害
　　６）糖尿病
　　
III　Risk factor up to date～リスク分類と１次治療選択～
　１．基調論文：海外のMedical Oncologistに訊く
　２．オピニオンリーダーに訊く
　　１）治療法選択の基本的考え方
　　２）進行性RCCにおける１次治療は何を根拠に選択するか？
　　３）転移性RCC薬物治療の現状と展望
　　４）今後の１次治療選択は？
　　５）IMDCリスク分類と１次治療選択
　　６）Intermediate risk症例をどのように治療すべきか？

IV　付録
　　RCC関連演題の一覧（ASCO 2018，AUA 2018，ESMO 2018）
　　索引
　　編集者プロフィール

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

[II] Topics of RCC～免疫チェックポイント阻害薬の副作用マネジメントの実際 ( IO - IO combinationを視野に入れて ) ～

P.25 掲載の参考文献

1) Robert C, et al. Nivolumab in previously untreat ed melanoma without BRAF mutation. N Engl J Med. 2015 ; 372 : 320-30.

2) Weber JS. Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. Am Soc Clin Oncol Educ Book. 2012 : 174-7.

3) Robert C, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015 ; 372 : 2521-32.

4) Beck KE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006 ; 24 : 2283-9.

5) 鈴木康夫 (研究代表者). 厚生労働科学研究費補助金難治性疾患等政策研究事業「難治性炎症性腸管障害に関する調査研究」 (鈴木班) 平成29年度分担研究報告書別冊. 2018. p.1. http://www.ibdjapan.org/pdf/doc01.pdf, (閲覧 : 2018-09-26)

6) 日本臨床腫瘍学会 (編). がん免疫療法ガイドライン. 東京 : 金原出版 ; 2016. p.38.

7) Bristol-Myers Squibb. OPDIVO? (nivolumab) highlights of prescribing information. 2018. https://packageinserts.bms.com/pi/pi_opdivo.pdf, (accessed 2018-09-26)

8) 奥村暢将, 他. 肺腺癌に対するニボルマブ投与後に潰瘍性大腸炎に類似した大腸炎を発症した1例. 日呼吸会誌. 2017 ; 6 : 445-9.

9) Brahmer J, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 ; 373 : 123-35.

10) Paz-Ares L, et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2015 ; 33 Suppl : LBA109.

11) Kawakami H, et al. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs. 2017 ; 35 : 529-36.

12) Gelsomino F, et al. A case of nivolumab-related cholangitis and literature review : how to look for the right tools for a correct diagnosis of this rare immune-related adverse event. Invest New Drugs. 2018 ; 36 : 144-6.

13) 佐藤辰宣, 他. び漫性に胆管および胆嚢壁肥厚像を呈したNivolumab関連胆管炎の1例. 胆道. 2018 ; 32 : 132-8.

14) Kashima J, et al. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer : a case report. Cancer Immunol Immunother. 2018 ; 67 : 61-5.

P.31 掲載の参考文献

1) Boutros C, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016 ; 13 : 473-86.

2) Howell M, et al. Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer. Lung Cancer. 2015 ; 88 : 117-23.

3) Puzanov I, et al. Managing toxicities associated with immune checkpoint inhibitors : consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017 ; 5 : 95.

4) Hassel JC, et al. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4) : Evaluation and management of adverse drug reactions. Cancer Treat Rev. 2017 ; 57 : 36-49.

5) Khoja L, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors : a systematic review. Ann Oncol. 2017 ; 28 : 2377-85.

P.37 掲載の参考文献

1) 小野薬品工業株式会社/ブリストル・マイヤーズスクイブ株式会社. オプジーボ(R), ヤーボイ(R) 腎細胞癌の適正使用ガイド. 2018-10. https://www.opdivo.jp/drug_info_files/drug_info/opdivo/tekisei/20000157/guide_rcc.pdf, (閲覧 : 2018-10-04)

2) Vansteenkiste J. Nivolumab for NSCLC in Japanese patients : similar benefits, but beware of pneumonitis. ESMO Open. 2017 ; 2 Suppl 1 : e000119.

3) Azuma A, et al. High Prevalence of Drug-induced Pneumonia in Japan. JMAJ. 2007 ; 50 : 405-11.

4) Larkin J, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015 ; 373 : 23-34.

5) 小野薬品工業株式会社/ブリストル・マイヤーズスクイブ株式会社. オプジーボ点滴静注適正使用に関する留意事項～間質性肺疾患の副作用について～. 2016-06. https://www.opdivo.jp/drug_info_files/drug_info/opdivo/tekisei/20000116/tekisei_pneumonia.pdf, (閲覧 : 2018-10-04)

6) MSD株式会社/大鵬薬品工業株式会社. キイトルーダ適正使用のお願い : 間質性肺疾患に対する留意事項. 2018-04. https://www.msdconnect.jp/static/mcijapan/images/interstitial_lung_disease_keytruda.pdf, (閲覧 : 2018-10-04)

7) Naidoo J, et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2017 ; 35 : 709-17.

8) 日本呼吸器学会 (編). 薬剤性肺障害の診断・治療の手引き. 東京 : メディカルレビュー社 ; 2012.

9) Haanen JBAG, et al. Management of toxicities from immunotherapy : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 ; 28 Suppl 4 : iv119-42.

10) Brahmer JR, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy : American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 ; 36 : 1714-68.

11) Pollack MH, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol. 2018 ; 29 : 250-5.

12) Delaunay M, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 2017 ; 50. pii : 1700050.

13) Cho JY, et al. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. Lung Cancer. 2018 ; 125 : 150-6.

14) MSD株式会社/大鵬薬品工業株式会社. キイトルーダ(R) 市販直後調査の結果報告. 2017-10. https://www.msdconnect.jp/static/mcijapan/images/eppv_keytruda_201710.pdf, (閲覧 : 2018-10-0

P.43 掲載の参考文献

1) Brahmer JR, et al. Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy : American Society of Clinical Oncology Clinical Practice Guideline. J Clin Onol. 2018 ; 36 : 1714-68.

2) Haanen JBAG, et al. Management of toxicities from immunotherapy : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 ; 28 Suppl 4 : iv119-42.

3) Gupta A, et al. Systematic review : colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther. 2015 ; 42 : 406-17.

4) Baxi S, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs : systematic review and meta-analysis. BMJ. 2018 ; 360 : k793.

5) Weber JS, et al. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012 ; 30 : 2691-7.

6) Kumar V, et al. Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Front Pharmacol. 2017 ; 8 : 49.

7) Marthey L, et al. Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. J Crohns Colitis. 2016 ; 10 : 395-401.

8) Dubin K, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016 ; 7 : 10391.

9) Berman D, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 2010 ; 10 : 11.

10) Bergqvist V, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother. 2017 ; 66 : 581-92.

P.47 掲載の参考文献

1) Zen Y, et al. Hepatotoxicity of immune checkpoint inhibitors : a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol. 2018 ; 31 : 965-73.

2) 坪内博仁, 他. 免疫抑制・化学療法により発症するB型肝炎対策-厚生労働省「難治性の肝・胆道疾患に関する調査研究」班劇症肝炎分科会および「肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究」班合同報告-. 肝臓. 2009 ; 50 : 38-42.

3) 厚生労働科学研究費補助金難治性疾患政策研究事業「難治性の肝・胆道疾患に関する調査研究」班自己免疫性肝炎分科会・原発性胆汁性胆管炎分科会, 他. 改訂自己免疫性肝炎・原発性胆汁性胆管炎診療ガイドライン. 肝臓. 2018 ; 59 : 211-6.

P.54 掲載の参考文献

1) Nishimura H, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001 ; 291 : 319-22.

2) 日本循環器学会. 急性および慢性心筋炎の診断・治療に関するガイドライン (2009年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2009_izumi_h.pdf, (閲覧 : 2018-10-25)

3) Lauer B, et al. Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol. 1997 ; 30 : 1354-9.

4) Liu PP, et al. Cardiovascular magnetic resonance for the diagnosis of acute myocarditis : prospects for detecting myocardial inflammation. J Am Coll Cardiol. 2005 ; 45 : 1823-5.

5) Johnson DB, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med. 2016 ; 375 : 1749-55.

6) Reuben A, et al. Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. Oncoimmunology. 2017 ; 6 : e1361097.

7) Tajiri K, et al. Immune checkpoint inhibitor-related myocarditis. Jpn J Clin Oncol. 2018 ; 48 : 7-12.

8) Semper H, et al. Drug-induced myocarditis after nivolumab treatment in a patient with PDL1-negative squamous cell carcinoma of the lung. Lung Cancer. 2016 ; 99 : 117-9.

9) Brustle K, et al. Checkpoint inhibitor induced cardiotoxicity : managing the drawbacks of our newest agents against cancer. Oncotarget. 2017 ; 8 : 106165-6.

10) Tajmir-Riahi A, et al. Life-threatening Autoimmune Cardiomyopathy Reproducibly Induced in a Patient by Checkpoint Inhibitor Therapy. J Immunother. 2018 ; 41 : 35-8.

P.62 掲載の参考文献

1) Osorio JC, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017 ; 28 : 583-9.

2) de Filette J, et al. Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab. J Clin Endocrinol Metab. 2016 ; 101 : 4431-9.

3) Antonia SJ, et al ; PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017 ; 377 : 1919-29.

4) Barroso-Sousa R, et al. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens : A Systematic Review and Meta-analysis. JAMA Oncol. 2018 ; 4 : 173-82.

5) Corsello SM, et al. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013 ; 98 : 1361-75.

6) Ryder M, et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma : a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014 ; 21 : 371-81.

7) Morganstein DL, et al. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin Endocrinol (Oxf). 2017 ; 86 : 614-20.

8) Joshi MN, et al. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction : clinical review. Clin Endocrinol (Oxf). 2016 ; 85 : 331-9.

9) McElnea E, et al. Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab. Orbit. 2014 ; 33 : 424-7.

10) Borodic GE, et al. Ipilimumab-induced orbital inflammation resembling Graves disease with subsequent development of systemic hyperthyroidism from CTLA-4 receptor suppression. Ophthalmic Plast Reconstr Surg. 2014 ; 30 : 83.

11) Faje A. Immunotherapy and hypophysitis : clinical presentation, treatment, and biologic insights. Pituitary. 2016 ; 19 : 82-92.

12) Caturegli P, et al. Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade : Insights into Pathogenesis from an Autopsy Series. Am J Pathol. 2016 ; 186 : 3225-35.

13) Iwama S, et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014 ; 6 : 230ra45.

14) Byun DJ, et al. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017 ; 13 : 195-207.

15) Dillard T, et al. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis : serious immune related adverse events across a spectrum of cancer subtypes. Pituitary. 2010 ; 13 : 29-38.

16) Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 ; 366 : 2443-54.

17) Gonzalez-Rodriguez E, et al ; Spanish Group for Cancer Immuno-Biotherapy (GETICA). Immune Checkpoint Inhibitors : Review and Management of Endocrine Adverse Events. Oncologist. 2016 ; 21 : 804-16.

18) Min L, et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis : a retrospective cohort study. Clin Cancer Res. 2015 ; 21 : 749-55.

19) Mahzari M, et al. Immune checkpoint inhibitor therapy associated hypophysitis. Clin Med Insights Endocrinol Diabetes. 2015 ; 8 : 21-8.

20) Trainer H, et al. Hyponatraemia secondary to nivolumab-induced primary adrenal failure. Endocrinol Diabetes Metab Case Rep. 2016 ; 2016. pii : 16-0108.

21) Min L, et al. Ipilimumab-induced autoimmune adrenalitis. Lancet Diabetes Endocrinol. 2013 ; 1 : e15.

22) Bacanovic S, et al. Ipilimumab-Induced Adrenalitis : A Possible Pitfall in 18F-FDG-PET/CT. Clin Nucl Med. 2015 ; 40 : e518-9.

23) Vudattu NK, et al. Humanized mice as a model for aberrant responses in human T cell immunotherapy. J Immunol. 2014 ; 193 : 587-96.

P.70 掲載の参考文献

1) 日本糖尿病学会 (編著). 糖尿病専門医研修ガイドブック改訂第7版. 東京 : 診断と治療社 ; 2017. p.65-9.

2) Imagawa A, et al. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med. 2000 ; 342 : 301-7.

3) Imagawa A, et al. Fulminant type 1 diabetes : a nationwide survey in Japan. Diabetes Care. 2003 ; 26 : 2345-52.

4) 今川彰久, 他. 1型糖尿病調査研究委員会報告-劇症2型糖尿病の新しい診断基準 (2012). 糖尿病. 2012 ; 55 : 815-20.

5) 吉田卓, 他. PD-1欠損と自己免疫感受性遺伝子. 炎症と免疫. 2007 ; 15 : 75-80.

6) Ansari MJ, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med. 2003 ; 198 : 63-9.

7) Fife BT, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol. 2009 ; 10 : 1185-92.

8) Wang J, et al. Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci U S A. 2005 ; 102 : 11823-8.

9) Hiromine Y, et al. Trinucleotide repeats of programmed cell death-1 gene are associated with susceptibility to type 1 diabetes mellitus. Metabolism. 2007 ; 56 : 905-9.

10) Fujisawa R, et al. Low programmed cell death-1 (PD-1) expression in peripheral CD4 (+) T cells in Japanese patients with autoimmune type 1 diabetes. Clin Exp Immunol. 2015 ; 180 : 452-7.

11) 小野薬品工業株式会社/ブリストル・マイヤーズスクイブ株式会社. オプジーボ点滴静注副作用件数一覧【単剤】. https://www.opdivo.jp/drug_info_files/drug_info/opdivo/tekisei/20000135/side_effect.pdf, (閲覧 : 2018-10-24)

12) Baden MY, et al. Characteristics and clinical course of type 1 diabetes mellitus related to antiprogrammed cell death-1 therapy. Diabetol Int. 2018. doi : 10.1007/s13340-018-0362-2.

13) Stamatouli AM, et al. Collateral Damage : Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes. 2018 ; 67 : 1471-80.

14) 日本糖尿病学会. 免疫チェックポイント阻害薬使用患者における1型糖尿病の発症に関するRecommendation (2016年8月18日). 2016-05. http://www.fa.kyorin.co.jp/jds/uploads/recommendation_nivolumab.pdf, (閲覧 : 2018-10-24)

15) 日本糖尿病学会 (編著). 糖尿病専門医研修ガイドブック改訂第7版. 東京 : 診断と治療社 ; 2017. p.269-71.

16) 日本糖尿病学会. 1型糖尿病の成因, 病態に関する調査研究委員会. 2018-06. http://www.jds.or.jp/modules/study/index.php?content_id=4, (閲覧 : 2018-10-24)

[III] Risk factor up to date～リスク分類と1次治療選択～

P.77 掲載の参考文献

1) Motzer RJ, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 ; 378 : 1277-90.

2) Escudier B, et al. CheckMate 214 : Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups [abstract]. Ann Oncol. 2017 ; 28 Suppl 5 : LBA5.

3) Choueiri TK, et al. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk : The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017 ; 35 : 591-7.

4) Motzer RJ, et al. IMmotion151 : A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC) [abstract]. J Clin Oncol. 2018 ; 36 Suppl 6S : 578.

P.86 掲載の参考文献

1) Motzer RJ, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 ; 378 : 1277-90.

2) Motzer RJ, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002 ; 20 : 289-96.

3) Heng DY, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents : results from a large, multicenter study. J Clin Oncol. 2009 ; 27 : 5794-9.

4) Heng DY, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model : a population-based study. Lancet Oncol. 2013 ; 14 : 141-8.

5) Rini BI, et al. Sunitinib in Patients With Metastatic Renal Cell Carcinoma : Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group. Clin Genitourin Cancer. 2018 ; 16 : 298-304.

6) Iacovelli R, et al. Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis? Clin Genitourin Cancer. 2018 ; 16 : 355-9. e1.

7) Choueiri TK, et al. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib : results from COMPARZ, a randomized controlled trial. Clin Cancer Res. 2015 ; 21 : 1071-7.

8) Miao D, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018 ; 359 : 801-6.

P.90 掲載の参考文献

1) Ishida Y, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992 ; 11 : 3887-95.

2) Wei SC, et al. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell. 2017 ; 170 : 1120-33.e17.

3) Chen DS, et al. Elements of cancer immunity and the cancer-immune set point. Nature. 2017 ; 541 : 321-30.

4) A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101). ClinicalTrials.gov Identifier : NCT02684006. https://clinicaltrials.gov/ct2/show/NCT02684006, (accessed 2018-10-18)

5) Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426). ClinicalTrials.gov Identifier : NCT02853331. https://clinicaltrials.gov/ct2/show/NCT02853331, (accessed 2018-10-18)

6) A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC) (IMmotion151). ClinicalTrials.gov Identifier : NCT02420821. https://clinicaltrials.gov/ct2/show/NCT02420821, (accessed 2018-10-18)

P.94 掲載の参考文献

1) Motzer RJ, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002 ; 20 : 289-96.

2) Naito S, et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era : a cooperative group report of 1463 patients. Eur Urol. 2010 ; 57 : 317-25.

3) Shinohara N, et al. A new prognostic classification for overall survival in Asian patients with previously untreated metastatic renal cell carcinoma. Cancer Sci. 2012 ; 103 : 1695-700.

4) Shinohara N, et al. Is Memorial Sloan-Kettering Cancer Center risk classification appropriate for Japanese patients with metastatic renal cell carcinoma in the cytokine era? Urol Oncol. 2013 ; 31 : 1276-82.

5) Motzer RJ, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007 ; 356 : 115-24.

6) Hudes G, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007 ; 356 : 2271-81.

7) Motzer RJ, et al. Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 ; 15 : 804-34.

8) Shinohara N, et al. Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy. Cancer Sci. 2015 ; 106 : 618-26.

9) Li P, et al. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras. Cancer Med. 2016 ; 5 : 169-81.

10) Heng DY, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents : results from a large, multicenter study. J Clin Oncol. 2009 ; 27 : 5794-9.

11) Motzer RJ, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 ; 373 : 1803-13.

12) Escudier B, et al. CheckMate 025 Randomized Phase 3 Study : Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. Eur Urol. 2017 ; 72 : 962-71.

13) Motzer RJ, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 ; 378 : 1277-90.

14) Powles T, et al. Updated European Association of Urology Guidelines Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer. Eur Urol. 2017 [Epub ahead of print]

15) McDermott DF, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018 ; 24 : 749-57.

16) Choueiri TK, et al. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100) : an open-label, dosefinding and dose-expansion, phase 1b trial. Lancet Oncol. 2018 ; 19 : 451-60.

P.98 掲載の参考文献

1) Ljungberg B, et al. EAU Guidelines on Renal Cell Carcinoma, 2018. http://uroweb.org/guideline/renal-cell-carcinoma/, (accessed 2018-10-25)

2) National Comprehensive Cancer Network. NCCN Guidelines, Kidney Cancer, Version 2. 2019. https://www.nccn.org/professionals/physician_gls/default.aspx, (accessed 2018-10-25)

3) Motzer RJ, et al ; CheckMate 214 Investigators. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 ; 378 : 1277-90.

4) Heng DY, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents : results from a large, multicenter study. J Clin Oncol. 2009 ; 27 : 5794-9.

5) Motzer RJ, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007 ; 356 : 115-24.

6) Sternberg CN, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma : results of a randomized phase III trial. J Clin Oncol. 2010 ; 28 : 1061-8.

7) Motzer RJ, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013 ; 369 : 722-31.

8) Choueiri TK, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial) : Progression-free survival by independent review and overall survival update. Eur J Cancer. 2018 ; 94 : 115-25.

9) Rini BI, et al. Sunitinib in Patients With Metastatic Renal Cell Carcinoma : Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group. Clin Genitourin Cancer. 2018 ; 16 : 298-304.

P.104 掲載の参考文献

1) Motzer RJ, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999 ; 17 : 2530-40.

2) Heng DY, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents : Results from a large multicenter study. J Clin Oncol. 2009 ; 27 : 5794-9.

3) Heng DY, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model : a population-based study. Lancet Oncol. 2013 ; 14 : 141-8.

4) Ruiz-Morales JM, et al. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma : Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur J Cancer. 2016 ; 65 : 102-8.

5) Perez-Valderrama B, et al. Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma : the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study. Ann Oncol. 2016 ; 27 : 706-11.

6) Motzer RJ, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 ; 378 : 1277-90.

7) Motzer RJ, et al. IMmotion 151 : A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC) [abstract]. J Clin Oncol. 2018 ; 36 Suppl 6S : 578.

8) Motzer RJ, et al. JAVELIN renal 101 : A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC) [abstract]. Ann Oncol. 2018 ; 29 Suppl 8 : LBA6_PR.

9) Rini BI, et al. Sunitinib in Patients With Metastatic Renal Cell Carcinoma : Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group. Clin Genitourin Cancer. 2018 ; 16 : 298-304.

10) Sella A, et al. Heterogeneity of Patients With Intermediate-Prognosis Metastatic Renal Cell Carcinoma Treated With Sunitinib. Clin Genitourin Cancer. 2017 ; 15 : 291-9.e1.

11) Iacovelli R, et al. Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis? Clin Genitourin Cancer. 2018 ; 16 : 355-9.e1.

12) Takamatsu K, et al. Prognostic Value of Baseline Serum C-Reactive Protein Level in Intermediate-Risk Group Patients With Metastatic Renal-Cell Carcinoma Treated by First-Line Vascular Endothelial Growth Factor-Targeted Therapy. Clin Genitourin Cancer. 2018 ; 16 : e927-33.

13) McKay RR, et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol. 2014 ; 65 : 577-84.

14) Tanaka N, et al. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy : A proposal of the modified-IMDC risk model. Urol Oncol. 2017 ; 35 : 39.e19-28.

15) McDermott DF, et al. Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC) : CheckMate 214 analysis [abstract]. Ann Oncol. 2018 ; 29 Suppl 8 : 874P.

書評

書評を投稿する

最近チェックした商品履歴

Loading...